logologo
QuantliQuantli

Myriad Genetics Inc

MYGN

NASDAQ

Biotechnology

$3.03

USD

-0.14 (-4.42%)

At close: Aug 14, 2026, 4:00 PM EDT

Market Cap $307.03M

Volume 1.6M

Price (USD)
Price (USD)

About Myriad Genetics Inc

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,700 full-time employees. The firm develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The firm is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

CEO

Mr. Samraat Raha

HQ

Salt Lake City, UTAH, US

Founded

1995

Employees

2,700

Quantli Score

8.4

Outperform

Fin. Health

8.1

Profitability

7.6

Growth

9.0

Cash-Flow Q.

8.8

Key Metrics

6 metrics our research team weighs before forming a view on MYGN.

Based on Quantli research · SEC filings · as of Q2 2026

METRIC

VALUE

CHANGE

TREND (3Y)

Revenue Growth (TTM)

-3.2%

-7.0 pp

Gross Margin (TTM)

68.8%

-1.6 pp

Operating Margin (TTM)

-12.2%

+37.9 pp

Net Margin (TTM)

-14.0%

+33.5 pp

ROE (TTM)

-37.1%

+64.8 pp

Free Cash Flow (TTM)

$-7.30M

Financial Snapshot

Full Financials

Revenue

$806.60M

-3.2%

YoY

Gross Margin

69%

TTM

-2.3%

YoY

Net Income

$-112.60M

+71.5%

YoY

Operating Cash Flow

$7.70M

+134.1%

YoY

Key Statistics

Open

$3.17

Previous Close

$3.17

Day Range

$3.01 - $3.18

52 Week Range

$2.74 - $8.59

Volume

1.6M

Average Volume (10 Days)

4.0M

Dividend Yield

Valuation Measurement

Market Cap

$307.03M

P/E Ratio (TTM)

P/S Ratio (TTM)

0.38

Price / Book

1.01

Financial Highlights

Profit Margin

-14.0%

Return on Assets

-17.6%

Return on Equity

-37.1%

Revenue (TTM)

$806.60M

Net Income (TTM)

$-112.60M

Diluted EPS (TTM)

-$1.19

Total Cash (MRQ)

$115.20M

Levered FCF (TTM)

$-7.30M

Turn research into action

Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.

Trend Following

Enter on trend. Cut losses fast.

Best for:

Active traders

Position Strategy

Ride market cycles. Patient hold.

Best for:

Patient investors

Swing Strategy

Buy support, sell on recovery.

Best for:

Risk-tolerant

Go deeper on MYGN

Similar Stocks

SION

Sionna Therapeutics Inc

$6.46

-1.2%

AVXL

Anavex Life Sciences Corp

$3.22

-1.5%

FATE

Fate Therapeutics Inc

$2.57

+2.0%

ANIK

Anika Therapeutics Inc

$21.50

+1.6%

SRZN

Surrozen Inc

$23.96

+1.0%

TRDA

Entrada Therapeutics Inc

$7.46

+0.1%

ALXO

ALX Oncology Holdings Inc

$1.96

+1.0%

ZSQR

Z Squared Inc (Delaware)

$3.94

-5.3%

ELDN

Eledon Pharmaceuticals Inc

$3.54

-4.3%

Earnings Calendar

Next Earnings

Estimated Q3 Release

Nov 02

Est. EPS

Adjusted consensus estimate

-$0.17